Ecnoglutide
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
Hangzhou Sciwind Biosciences Co · Phase 3 · Completed · Enrollment 664
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| C1- XW003 Low Dosage | n/r | n/r | n/r | n/r |
| C1-Placebo | n/r | n/r | n/r | n/r |
| C2- XW003 Medium Dosage | n/r | n/r | n/r | n/r |
| C2-Placebo | n/r | n/r | n/r | n/r |
| C3- XW003 High Dosage | n/r | n/r | n/r | n/r |
| C3-Placebo | n/r | n/r | n/r | n/r |
Not shown
- C1- XW003 Low Dosage: endpoint not reported
- C1-Placebo: endpoint not reported
- C2- XW003 Medium Dosage: endpoint not reported
- C2-Placebo: endpoint not reported
- C3- XW003 High Dosage: endpoint not reported
- C3-Placebo: endpoint not reported